Vertanical has received marketing authorization in Germany for Exilby — a first-in-class non-opioid treatment for chronic low back pain with a radicular neuropathic component. The product is based on two pivotal Phase 3 trials involving over 1,200 patients that demonstrated significant pain reduction, a favorable tolerability profile, and no evidence of dependence, with a head-to-head comparator study showing superior pain relief and better gastrointestinal tolerability than opioids.
Exilby is a standardized full-spectrum extract derived from a proprietary Cannabis sativa strain, containing a defined mixture of cannabinoids, terpenes, and other bioactive compounds selected specifically for pain modulation. The non-opioid treatment has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration, with a pivotal U.S. Phase 3 trial already underway and a potential New Drug Application planned for 2028.
Non-Opioid Chronic Pain Treatments
Vertanical Advances Its Non-Opioid Treatment in Germany
Trend Themes
-
Non-opioid Pain Relief — Regulatory validation of dependence-free chronic pain therapies creates space for analgesic portfolios that challenge opioid incumbents in long-term care.
-
Cannabis-derived Pharmaceuticals — Standardized full-spectrum extracts with defined cannabinoid and terpene profiles signal a shift from wellness cannabis toward clinically validated prescription medicines.
-
Evidence-based Neuropathic Care — Phase 3 data for radicular neuropathic pain highlights commercial potential in targeted treatments for pain subtypes that remain underserved by broad analgesics.
Industry Implications
-
Pharmaceuticals — First-in-class approvals for novel pain compounds create competitive openings for drugmakers seeking safer chronic-use therapies with strong differentiation.
-
Pain Management — Clinics and specialist care networks may see new treatment pathways emerge as non-opioid options demonstrate efficacy, tolerability, and reduced dependence risk.
-
Medical Cannabis — Prescription-grade cannabis formulations backed by pivotal trials expand the sector beyond consumer products into regulated therapeutic markets.